Breaking News Instant updates and real-time market news.

NVS

Novartis

$83.27

0.11 (0.13%)

05:36
07/18/17
07/18
05:36
07/18/17
05:36

Novartis backs FY17 revenue guidance of 'broadly in line with the prior year'

Novartis provided the following FY17 outlook: "We re-confirm our Group outlook as presented at the beginning of 2017. Group net sales in 2017 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition, including the continued genericization of Gleevec/Glivec in the U.S. and Europe. From a divisional perspective, we expect net sales performance in 2017 to be as follows: Innovative Medicines: broadly in line with prior year, to a slight increase; Sandoz: broadly in line with prior year; Alcon: revised upward to low single digit growth. Group core operating income in 2017 is expected to be broadly in line with prior year to a low single digit decline. If mid-July exchange rates prevail for the remainder of 2017, the currency impact for the year would be negative 1 percentage point on net sales and negative 2 percentage points on core operating income."

  • 18

    Jul

NVS Novartis
$83.27

0.11 (0.13%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.

TODAY'S FREE FLY STORIES

BLUE

bluebird bio

$171.15

3.25 (1.94%)

20:25
12/10/17
12/10
20:25
12/10/17
20:25
Conference/Events
bluebird bio to hold a webcast »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

DIS

Disney

$104.23

-0.19 (-0.18%)

, GOOG

Alphabet

$1,037.05

6.12 (0.59%)

20:06
12/10/17
12/10
20:06
12/10/17
20:06
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

DIS

Disney

$104.23

-0.19 (-0.18%)

GOOG

Alphabet

$1,037.05

6.12 (0.59%)

GOOGL

Alphabet Class A

$1,049.38

4.81 (0.46%)

DAL

Delta Air Lines

$53.46

0.05 (0.09%)

BRK.A

Berkshire Hathaway

$294,385.33

285.33 (0.10%)

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

PXD

Pioneer Natural

$155.90

1.65 (1.07%)

AMAT

Applied Materials

$51.43

-0.87 (-1.66%)

EPD

Enterprise Products

$24.94

0.25 (1.01%)

ALLY

Ally Financial

$28.65

0.28 (0.99%)

ANTM

Anthem

$224.85

1.21 (0.54%)

USFD

US Foods

$31.00

0.38 (1.24%)

TJX

TJX

$73.88

0.04 (0.05%)

ROST

Ross Stores

$76.89

0.19 (0.25%)

MBI

MBIA

$8.08

-0.01 (-0.12%)

CVS

CVS Health

$73.09

2 (2.81%)

T

AT&T

$36.73

0.56 (1.55%)

DISH

Dish

$48.59

-0.36 (-0.74%)

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

TM

Toyota

$124.45

1.06 (0.86%)

SFTBY

SoftBank

$41.62

-0.02 (-0.05%)

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

  • 14

    Dec

  • 09

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 08

    May

AKTX

Akari Therapeutics

$4.90

-0.14 (-2.78%)

19:25
12/10/17
12/10
19:25
12/10/17
19:25
Conference/Events
Akari Therapeutics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

BMRN

BioMarin

$81.99

1.09 (1.35%)

, ALXN

Alexion

$114.46

7.68 (7.19%)

19:11
12/10/17
12/10
19:11
12/10/17
19:11
Recommendations
BioMarin, Alexion, Celgene analyst commentary at Piper Jaffray »

Piper Jaffray remains…

BMRN

BioMarin

$81.99

1.09 (1.35%)

ALXN

Alexion

$114.46

7.68 (7.19%)

CELG

Celgene

$106.09

3.36 (3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 08

    Jan

  • 18

    Jan

  • 28

    Feb

  • 25

    Mar

TWX

Time Warner

$90.71

0.34 (0.38%)

, CMCSA

Comcast

$37.95

0.06 (0.16%)

18:50
12/10/17
12/10
18:50
12/10/17
18:50
Hot Stocks
Box Office Battle: 'Coco' stays number 1 with $18.3M »

Disney (DIS) and…

TWX

Time Warner

$90.71

0.34 (0.38%)

CMCSA

Comcast

$37.95

0.06 (0.16%)

CMCSK

Comcast

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

LGF.A

Lionsgate

$31.56

-0.07 (-0.22%)

DIS

Disney

$104.23

-0.19 (-0.18%)

VIAB

Viacom

$29.29

-0.35 (-1.18%)

VIA

Viacom

$34.00

-0.25 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:38
12/10/17
12/10
18:38
12/10/17
18:38
Periodicals
Volkswagen CEO suggests ending diesel vehicles subsidies, NY Times reports »

Volkswagen CEO said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

18:35
12/10/17
12/10
18:35
12/10/17
18:35
Periodicals
Hospital giants in talks to merge, WSJ reports »

Ascension and Providence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:27
12/10/17
12/10
18:27
12/10/17
18:27
Periodicals
Volkswagen executive may ask to serve sentence in Germany, Reuters says »

Volkswagen executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGP

GGP

$23.43

0.03 (0.13%)

, BPY

Brookfield Property

$21.61

0.08 (0.37%)

18:21
12/10/17
12/10
18:21
12/10/17
18:21
Periodicals
Mall owner GGP rejects Brookfield Property buyout offer, Reuters reports »

U.S. mall owner GGP (GGP)…

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$17.96

0.01 (0.06%)

18:16
12/10/17
12/10
18:16
12/10/17
18:16
Recommendations
AtriCure analyst commentary at Piper Jaffray »

Piper Jaffray remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:11
12/10/17
12/10
18:11
12/10/17
18:11
Hot Stocks
Karyopharm presents positive phase 1/2 Eltanexor data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:09
12/10/17
12/10
18:09
12/10/17
18:09
Hot Stocks
Karyopharm presents positive Selinexor data from STOMP study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

18:05
12/10/17
12/10
18:05
12/10/17
18:05
Hot Stocks
Agios Pharmaceuticals presents updated data from DRIVE PK study »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ICL

ICL

$4.03

-0.07 (-1.71%)

18:01
12/10/17
12/10
18:01
12/10/17
18:01
Hot Stocks
ICL completes sale of 50% share of IDE Technologies for $167M »

ICL announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$32.74

0.52 (1.61%)

17:52
12/10/17
12/10
17:52
12/10/17
17:52
Hot Stocks
AstraZeneca Calquence shows potential in chronic lymphocytic leukemia trials »

AstraZeneca and Acerta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

, XON

Intrexon

$13.28

0.16 (1.22%)

17:48
12/10/17
12/10
17:48
12/10/17
17:48
Hot Stocks
Ziopharm announces presentation of data from T-Cell Therapy programs »

Ziopharm Oncology (ZIOP)…

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

XON

Intrexon

$13.28

0.16 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:45
12/10/17
12/10
17:45
12/10/17
17:45
Hot Stocks
bluebird bio announces results from LentiGlobin study in Severe Sickle Cell »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:37
12/10/17
12/10
17:37
12/10/17
17:37
Hot Stocks
bluebird bio presents new data from clinical studies of LentiGlobin Gene Therapy »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

VSTM

Verastem

$4.33

0.36 (9.07%)

17:35
12/10/17
12/10
17:35
12/10/17
17:35
Hot Stocks
Verastem announces phase 3 DUO study met primary endpoint »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

CELG

Celgene

$106.09

3.36 (3.27%)

, BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:30
12/10/17
12/10
17:30
12/10/17
17:30
Hot Stocks
Celgene, bluebird bio announce updated results from CRB-401 Phase 1 study »

Celgene (CELG) and…

CELG

Celgene

$106.09

3.36 (3.27%)

BLUE

bluebird bio

$171.15

3.25 (1.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

GILD

Gilead

$74.22

1.5 (2.06%)

17:22
12/10/17
12/10
17:22
12/10/17
17:22
Hot Stocks
Kite announces long-term data from pivotal ZUMA-1 study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EPZM

Epizyme

$13.25

0.25 (1.92%)

17:18
12/10/17
12/10
17:18
12/10/17
17:18
Hot Stocks
Epizyme presents new biomarker data on Tazemetostat »

Epizyme announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

17:16
12/10/17
12/10
17:16
12/10/17
17:16
Hot Stocks
Study shows Bioverativ Eloctate has potential to improve bleed protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:04
12/10/17
12/10
17:04
12/10/17
17:04
Hot Stocks
Syros Pharmaceuticals announces new preclinical data on SY-1365 »

Syros Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:00
12/10/17
12/10
17:00
12/10/17
17:00
Hot Stocks
Syros Pharmaceuticals announces initial data from phase 2 trial of SY-1425 »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.